Discontinue 2 memorize results: VEGF Trap-Eye improves envisioning in patients with DME
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye showed thetical results in a Slant gradually introduce 2 review in patients with diabetic macular edema (DME). The predominant endpoint of the retreat, a statistically meaningful advance in visual acuity from 24 weeks compared to the definitive of heed in DME, macular laser remedy, was met. Visual acuity recovery was unhurried near the middle count of letters gained past the inaugural 24 weeks of the con.
"The faculty of VEGF Trap-Eye to significantly make progress mirage in patients with DME in this inaugural Moment 2 retreat is encouraging," said Dr. Kemal Malik, colleague of the Bayer HealthCare Kingpin Cabinet chargeable as a remedy for far-reaching incident. "Bayer and Regeneron inclination converse about the next steps in ;martial developing VEGF Trap-Eye in this indication."
"The importance of the obtain in visual acuity achieved with VEGF Trap-Eye in this Side 2 investigation demonstrates the biologic movement of VEGF Trap-Eye in on the move diabetic macular edema, a blight in which euphoric levels of vascular endothelial lump aspect (VEGF) are pass out," said Diana Do, MD, the Starring Investigator fitting for the con and Mix Professor of Ophthalmology at the Wilmer Contemplate Set up, The Johns Hopkins University Form of Nostrum in Baltimore, Maryland.
Patients in each of the four dosing groups receiving VEGF Trap-Eye achieved statistically significantly greater bad improvements in visual acuity (8.5 to 11.4 letters of perspective gained) compared to patients receiving macular laser treatment (2.5 letters gained) at week 24 (p< 0.01 proper for each VEGF Trap-Eye assemble versus laser). VEGF Trap-Eye was typically manifestly tolerated, and there were no drug-related vital adverse events.
The results of the Put a stop to 2 sanctum sanctorum devise be presented at the Angiogenesis 2010: Clinical Trials conjunction on February 20, 2010 in Miami, Florida. Slides summarizing the facts presented desire be made close by at that tempo on the Regeneron website (www.regeneron.com on the Presentations Time, care of the Investor Relations split.
DOCUMENTATION Regeneron Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
